Functional and quality of life outcomes after partial glossectomy: a multi-institutional longitudinal study of the head and neck research network

Agnieszka Dzioba 1,2*, Daniel Aalto 2,3,9, Georgina Papadopoulos-Nydam 2,3, Hadi Seikal 1,2,4, Jana Rieger 2,3, Johan Wolfardt 1,4, Martin Osswald 1,2,4, Jeffrey R. Harris 1,2,4, Daniel A. O’Connell 1,4, Cathy Lazarus 5,6, Mark Urken 5,6, Ilya Likhterov 5,6, Raymond L. Chai 5,6, Erika Rauscher 6, Daniel Buchinder 6,7, Devin Okay 6,7, Risto-Pekka Happonen 8,9, Ilpo Kinnunen 10, Irjala Heikki 10, Tero Soukka 8,9, Juhani Laine 8,9 and Head and Neck Research Network

Abstract

**Background:** While aggressive treatment for oral cancer may optimize survival, decrements in speech and swallowing function and quality of life often result. This exploratory study investigated how patients recover their communicative function, swallowing ability, and quality of life after primary surgery [with or without adjuvant (chemo)radiation therapy] for tongue cancer over the course of the first year post-operation.

**Methods:** Patients treated for oral cancer at three institutions (University of Alberta Hospital, Mount Sinai Beth Israel Medical Center, and Turku University Hospital) were administered patient-reported outcomes assessing speech [Speech Handicap Index (SHI)], swallowing [(M.D. Anderson Dysphagia Inventory (MDADI)] and quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-H&N35)]. Outcome measures were completed pre-operatively and at 1-, 6-, and 12-months post-operatively.

**Results:** One hundred and seventeen patients undergoing partial glossectomy with reconstruction participated in this study. Results indicated no significant differences in swallowing function (MDADI and EORTC-H&N35 subscales) between baseline and 6 months post-surgery and no significant differences in speech function (SHI subscales) between baseline and 1 year post-surgery. Most quality of life domains (EORTC-H&N35 subscales) returned to baseline levels by 1 year post-operation, while difficulties with dry mouth and sticky saliva persisted. A clear time trend of adjuvant (chemo)radiation therapy negatively affecting dry mouth scores over time was identified in this study, while negative independent effects of chemoradiation on MDADI swallowing, and EORTC-H&N35 swallowing, eating, and opening mouth subscales were found.

**Conclusions:** Assessment time influenced patient-reported speech, swallowing, and quality of life outcomes, while treatment (by time) effects were found for only swallowing and quality of life outcomes. Results of the present study will help guide clinical care and will be useful for patient counseling on expected short and long-term functional and quality of life outcomes of surgical and adjuvant treatment for oral cavity cancer.

**Keywords:** Oral cancer, Quality of life, Speech, Swallowing, Patient-reported outcome

* Correspondence: adzioba@ualberta.ca

1Department of Surgery, University of Alberta Hospital, Edmonton, AB T6G 2G4, Canada

2Institute for Reconstructive Sciences in Medicine (iRSM), Misericordia Community Hospital, Edmonton, AB, Canada

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Individuals suffering with cancer of the oral tongue undergo multiple treatment regimens. The standard of care for patients presenting with a tumour in the anterior tongue includes partial glossectomy, as it offers the best survival benefit to the patient [1–4]. Furthermore, adjuvant radiation therapy (RT) or chemoradiation therapy (CRT) are also often indicated [5–7]. These aggressive combinations of treatment modalities have resulted in significant improvement in survival outcomes, but the effects on quality of life and survivorship remain profound [5, 8, 9].

Recently, patient and clinician driven interest in functional outcomes related to different treatment regimens have highlighted the need for this information to customize treatment for individual patients while optimizing survival and function. Current literature assessing functional outcomes has lacked standardization in the tools used, follow-up times and reporting methods, making it difficult to draw conclusions in a systematic way [9–12].

The Head and Neck Research Network (HNRN) is a multi-disciplinary international research organization dedicated to advancing treatment for head and neck cancer (HNC) through functional outcomes research. This network was founded by three partnering international centers in Edmonton, Alberta, Canada; Turku, Finland; and, New York, New York, USA. The HNRN maintains an international database with clinically-significant data and integrity, allowing for the collection of outcomes data in a standardized fashion and facilitating the conduct of collaborative research on function and quality of life in patients with HNC.

Individuals suffering with oral cancer experience life altering deficits, due in most part to treatment effects on the tongue, jaws, throat, salivary glands, and the sensory systems of the head and neck [10, 13–15]. This in turn results in severe deficits in speaking, eating, and appearance, significantly impacting the physical and psychosocial health of patients [10, 11, 15, 16]. Furthermore, it is well acknowledged that treatment modality may differentially affect the functioning and quality of life of patients with oral cavity cancer [5, 6, 9].

The purpose of the present exploratory study of the HNRN was to answer the following research questions:

1) Are there differences in self-perceived functional and quality of life outcomes between pre-treatment and at three post-operative time-points (1-, 6-, and 12-months) in patients treated with primary surgery (with or without C/RT) and reconstruction for cancer of the oral tongue?

2) Are speech, swallowing, and quality of life outcomes influenced by treatment modality [primary surgery only (Sx), primary surgery and adjuvant radiation therapy (Sx-RT), primary surgery and adjuvant chemoradiation therapy (Sx-CRT)] in patients with oral cancer?

Methods

This multi-institutional longitudinal study was conducted at three HNRN centers between January 2010 and September 2015. The centers included: the University of Alberta Hospital and Institute for Reconstructive Sciences in Medicine in Edmonton, Alberta, Canada; Turku University Hospital in Turku, Finland; and Mount Sinai Beth Israel Medical Center in New York, New York, USA. Prior to commencement of data collection, this study received ethical approval from the Health Research Ethics Boards of each participating institution.

Participants

Patients undergoing primary surgery for cancer of the oral cavity (anterior two-thirds of the tongue) were prospectively recruited. All patients were diagnosed with SCCA and were treated with a partial glossectomy with or without floor of mouth resection and with or without resection of the mandible. Reconstruction was completed with a free tissue transfer (most commonly radial forearm free flap) when deemed appropriate by the resection surgeon. When indicated, patients also received adjuvant C/RT for their cancer treatment. Dose of radiation ranged between 60 to 72 Gy. Patients for whom the resection had extended to other structures of the oral and oropharyngeal areas (e.g., buccal mucosa, base of tongue, etc.), patients who received previous oncological treatment in the head and neck region, and patients with existing speech or swallowing disorders or cognitive impairment were excluded from the study.

Outcome measures

Patients attended pre-treatment and post-surgical appointments at their respective medical center to assess their functional status related to speech and swallowing, as well as quality of life. As part of a standard clinical protocol, the following patient-reported outcomes were administered to and self-completed by patients in a quiet, private setting: 1) the Speech Handicap Index (SHI) [12, 17, 18]; 2) the M.D. Anderson Dysphagia Inventory (MDADI) [19–21]; and, 3) the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC-H&N35) [22–24] (see Additional file 1 for description of outcome measures). For the Turku center, Finnish translated versions of the SHI, MDADI, and EORTC-H&N35 were administered to study participants. The SHI, MDADI, and EORTC-H&N35 were completed at four time points: pre-operatively, and at 1 month, 6 month, and 1 year post-operative intervals as part of routine patient follow-up.

Statistical analysis

This exploratory study investigated the impact of treatment modality and assessment time on patients’
self-perceived speech and swallowing function and quality of life. In addition to descriptive statistics, mixed effects regression models were fitted to every subscale of the three outcome measures: SHI, MDADI, and EORTC-H&N35, resulting in 18 models (see Additional files 2 and 3 for details of statistical analysis and participant recruitment flowchart, respectively). To account for the missing data, maximum likelihood estimates were used for estimating the parameters of the mixed effects linear regression models since they can handle missing data points robustly without discarding any data [25]. A Bonferroni correction was applied to the .05 alpha level to adjust for the 18 mixed effects regression analyses that were completed [26]. Hence, statistical significance was set a priori at the .0028 alpha level for final interpretation of mixed effects analyses. Statistical analyses were performed using SPSS (Version 22.0).

Results

Table 1 displays patient demographic and treatment-related information. One hundred and seventeen patients participated in this study. Mean age of patients was 58.2 years with a standard deviation of 13.3 years. Males comprised 63% of study participants. Descriptive statistics for the SHI, MDADI, and EORTC-H&N35 are displayed in Additional file 4. Results of the mixed effects regression analyses identified differences in speech and swallowing function, and quality of life reported by patients with oral cancer of the tongue between pre-operation and follow-up assessment time points; treatment (by time) effects were also observed for the MDADI and EORTC-H&N35, but not for the SHI.

Speech function

Table 2 displays results of mixed effects regression models for the SHI outcome measure. Three mixed effects linear regression models were fitted to the SHI total and subscale (Psychosocial, Speech) scores. No statistically significant interactions between treatment and assessment time, nor any significant results for the main effect of treatment were found. At 1 month post-operation, statistically significantly higher total SHI (+10.0, \(p = .002\)) and Speech subscale (+5.4, \(p < .001\)) scores compared with baseline scores were observed for the combined cohort. At 6 months post-operation, a statistically significantly higher score was found for only the Speech subscale (+4.7, \(p = .002\)) of the SHI compared with baseline. At 1 year post-operation, no statistically significant results were

| Demographic Variable | Edmonton (n = 63) | New York (n = 41) | Turku (n = 13) | Total (n = 117) |
|----------------------|-------------------|------------------|---------------|----------------|
| Sex                  |                   |                  |               |                |
| Male                 | 39 (62)           | 27 (66)          | 5 (38)        | 71 (61)        |
| Female               | 24 (38)           | 14 (34)          | 8 (62)        | 46 (39)        |
| T-stage at diagnosis |                   |                  |               |                |
| T1                   | 2 (3)             | 8 (20)           | 3 (23)        | 13 (11)        |
| T2                   | 44 (70)           | 8 (20)           | 7 (54)        | 59 (50)        |
| T3                   | 14 (22)           | 9 (22)           | 3 (23)        | 26 (22)        |
| T4                   | 3 (5)             | 7 (17)           | 0 (0)         | 10 (9)         |
| Unknown              | 0 (0)             | 9 (22)           | 0 (0)         | 9 (8)          |
| AJCC Staging         |                   |                  |               |                |
| Stage                | 2 (3)             | 6 (15)           | 2 (15)        | 10 (9)         |
| Stage II             | 27 (43)           | 4 (10)           | 4 (31)        | 35 (29)        |
| Stage III            | 16 (25)           | 2 (5)            | 2 (15)        | 20 (17)        |
| Stage IV             | 18 (29)           | 20 (49)          | 5 (38)        | 43 (37)        |
| Unknown              | 0 (0)             | 9 (22)           | 0 (0)         | 9 (8)          |
| Treatment            |                   |                  |               |                |
| Sx                   | 29 (46)           | 15 (37)          | 6 (46)        | 50 (43)        |
| Sx/RT                | 17 (27)           | 10 (24)          | 0 (0)         | 27 (23)        |
| Sx/CRT               | 17 (27)           | 16 (39)          | 7 (54)        | 40 (34)        |
| Surgical Approach    |                   |                  |               |                |
| Transoral            | 54 (86)           | 21 (51)          | 8 (61)        | 83 (71)        |
| Transmandibular      | 6 (10)            | 12 (29)          | 1 (8)         | 19 (16)        |
| Unknown              | 3 (5)             | 8 (20)           | 4 (31)        | 15 (13)        |
| Reconstruction       |                   |                  |               |                |
| RFFF                 | 40 (64)           | 19 (46)          | 7 (54)        | 66 (56)        |
| Other                | 7 (11)            | 6 (14)           | 0 (0)         | 13 (11)        |
| Unknown              | 16 (25)           | 16 (39)          | 6 (46)        | 38 (32)        |

Abbreviations: AJCC American Joint Committee on Cancer, Sx surgery, Sx/RT primary surgery and adjuvant radiation therapy, Sx/CRT primary surgery and adjuvant chemoradiation therapy, RFFF radial forearm free flap
found. No statistically significant results were found for the Psychosocial subscale of the SHI for any comparison period. However, according to the 6 point cut-off score established by the developers of the SHI [17], estimated mean total SHI scores at all time points (pre-op: 20.9, 1 month: 30.8, 6 months: 30.1, 1 year: 28.5) indicate clinically relevant self-reported speech impairment.

Swallowing function
Table 3 displays results of mixed effects regression models for the MDADI outcome measure. Three mixed effects linear regression models were fitted to the MDADI subscale (Emotional, Functional, Physical) scores. Regression analyses for the MDADI subscale scores did not reveal any statistically significant interactions between treatment and assessment time. However, when the interaction term was removed from the models, treatment and time effects were revealed for all three MDADI subscales.

Treatment effects
Statistically significant greater impairment in the Emotional ($-8.6, p = .002$), Functional ($-13.1, p < .001$) and Physical ($-9.7, p = .002$) subscales of the MDADI were found for patients in the Sx-CRT group compared with baseline scores. No statistically or clinically relevant differences in MDADI subscale scores were found for patients in the Sx-RT group compared with baseline.

Time effects
At 1 month post-operation, statistically significantly greater impairment was observed for the Emotional ($-6.5, p < .001$), Functional ($-8.3, p < .001$) and Physical ($-7.1, p < .001$) subscales of the MDADI compared with estimated mean baseline scores for the combined study cohort. No statistically significant differences were found between baseline and 6 months, and baseline and 1 year post-operation for the subscales of the MDADI. However, when examining individual scores, a clinically significant ($\geq 20$ point) drop in MDADI subscale scores between baseline and 1 month (33%, 33%, 23%), 6 months (22%, 30%, 31%), and 1 year (22%, 20%, 22%) for the Emotional, Functional and Physical subscales respectively, was observed in the present study.

Quality of life related to head and neck cancer
Table 4 displays results of mixed effects regression models for the EORTC-H&N35 outcome measure. Twelve mixed effects linear regression models were fitted to the EORTC-H&N35 subscale (Pain, Swallowing, Senses, Speech, Eating, Social Contact, Sexuality, Teeth, Opening Mouth, Dry Mouth, Saliva, Cough) scores. Treatment by time interactions, treatment effects, and time effects were revealed for the EORTC-H&N35.

Treatment by time interactions
Statistically significant treatment by time interactions were observed for only the Dry Mouth subscale of the EORTC-H&N35. At 1 month post-operation, clinically (>10 points) significant worse Dry Mouth scores were observed for the Sx-CRT (+14.9, $p = .104$) compared with baseline. At 6 months post-operation, clinically and statistically worse symptoms of Dry Mouth were observed for both the Sx-RT (+42.2, $p < .001$), and Sx-CRT (+36.5, $p < .001$) groups compared with baseline. At 1 year post-operation, Dry Mouth scores remained clinically and statistically worse than baseline for both the Sx-RT (+35.3, $p < .001$).
and Sx-CRT (+33.03, p < .001) groups. No clinically or statistically significant differences in Dry Mouth were found between baseline and all post-operative assessments for the Sx group.

**Treatment effects**

For three outcome variables of the EORTC-H&N35 (Eating, Opening Mouth, Swallowing), an independent treatment effect was observed. Statistically and clinically significantly greater difficulties with Eating (+14.3, p = .003), and Opening Mouth (+14.6, p = .002), and clinically (>10 points) greater difficulties with Swallowing (+10.4, p = .006), were reported for the Sx-CRT group compared with baseline. No significant differences were observed for the Sx-RT group compared with baseline for Eating, Opening Mouth, or Swallowing.

**Time effects**

For five outcome variables of the EORTC-H&N35 (Pain, Swallowing, Senses, Open Mouth, Sticky Saliva), mixed effects regression models revealed differences in estimated mean scores between baseline and post-operative assessment scores for the combined cohort. At 1 month post-operation, statistically and clinically significantly less Pain (−13.2, p < .001), and more difficulties with Swallowing (+10.1, p < .001), and Opening Mouth (+12.4, p < .001) compared with baseline were observed. At 6 months post-operation, statistically and clinically significantly less Pain (−15.7, p < .001) and more problems with Sticky Saliva (+15.3, p < .001), clinically (>10 points) more difficulties with Opening Mouth (+11.3, p = .004), and statistically (but not clinically) significantly greater impairments with Senses (+8.9, p < .001) compared to baseline were found. No statistically or clinically significant treatment by time interactions, treatment effects, or time effects were found for Speech, Social Contact, Sexuality, Teeth, or Cough subscales of the EORTC-H&N35.

**Discussion**

The purpose of this exploratory study was to evaluate self-reported speech and swallowing function, as well as quality of life, over the course of the first year post-operation and the impact of treatment modality on functional outcome in patients surgically treated for tongue cancer. To our knowledge, this is the first longitudinal study evaluating the functional and quality of life effects of surgical treatment for SCCA in patients suffering with cancer of the oral tongue. This multi-center study of the HNRN included a large sample (n = 117) of patients with cancer of the anterior tongue. By allowing institutions to collaborate in a structured manner, the HNRN approach offers a valuable research method for advancing functional outcomes.

---

**Table 3** Mixed effects linear regression models for M.D. Anderson Dysphagia Inventory

| Subscale (n) | Variable | Estimate | 95% CI   | SE  | t   | p      | SDs of Random Effects |
|-------------|----------|----------|----------|-----|-----|--------|-----------------------|
|             | Intercept| Residual |          |     |     |        |           |
| Emotional (n = 112) | Baseline | 79.40 | 75.3 to 83.5 | 2.08 | 38.25 | .938 | 12.27 |
|             | Sx-RT    | −4.58 | −10.4 to +1.3 | 2.94 | −1.56 | .122 |
|             | Sx-CRT   | −8.64 | −13.3 to −4.0 | 2.68 | −3.22 | .002* |
|             | 1 month  | −6.45 | −10.0 to −2.9 | 1.90 | −3.39 | <.001* |
|             | 6 month  | −3.34 | −7.2 to +5.0  | 1.97 | −1.69 | .092 |
|             | 1 year   | −3.61 | −7.9 to +6.2  | 2.16 | −1.67 | .095 |
| Functional (n = 112) | Baseline | 84.32 | 79.6 to 89.0 | 2.38 | 35.48 | .1170 | 12.93 |
|             | Sx-RT    | −5.62 | −12.3 to +1.2 | 3.45 | −1.63 | .107 |
|             | Sx-CRT   | −13.08| −19.9 to −6.1 | 3.15 | −4.15 | <.001* |
|             | 1 month  | −8.31 | −14.4 to −2.2 | 2.02 | −4.11 | <.001* |
|             | 6 month  | −5.95 | −10.1 to −1.9 | 2.09 | −2.85 | .005 |
|             | 1 year   | −3.96 | −8.5 to +5.0  | 2.29 | −1.73 | .085 |
| Physical (n = 112)  | Baseline | 77.85 | 73.4 to 82.3 | 2.29 | 34.05 | .1101 | 12.75 |
|             | Sx-RT    | −7.34 | −8.0 to −13.8 | 3.30 | −2.23 | .028 |
|             | Sx-CRT   | −9.74 | −9.9 to −15.5 | 3.01 | −3.24 | .002* |
|             | 1 month  | −7.09 | −11.0 to −3.3 | 1.99 | −3.57 | <.001* |
|             | 6 month  | −3.58 | −7.6 to +5.0  | 2.05 | −1.74 | .084 |
|             | 1 year   | −3.46 | −8.0 to +9.1  | 2.25 | −1.54 | .126 |

Note. *p < .0028; Baseline = pre-operative mean estimate for surgery only group; Sx-RT, Sx-CRT = difference between pre-operative mean scores and baseline for surgery and radiotherapy, and, surgery and chemoradiotherapy groups, respectively; 1 month/6 months/1 year = difference between mean subscale score and baseline for the respective assessment time point for combined cohort; p-value for baseline scores not provided given that it tests the hypothesis that the baseline mean is significantly different from 0, results of which are not clinically meaningful; 95% CI calculated using bootstrapping approach.
Table 4 Mixed effects linear regression models for EORTC Quality of Life Questionnaire Head and Neck Module (EORTC-H&N35)

| Subscale (n) | Variable | Estimate | 95% CI | SE  | t    | p      | SDs of Random Effects |
|--------------|----------|----------|--------|-----|------|--------|-----------------------|
|              |          |          |        |     |      |        | Intercept             |
|              |          |          |        |     |      |        | Residual              |
| Pain (n = 109) | Baseline | 36.54    | 32.1 to 40.9 | 2.26 | 16.20| <.001* | 17.30                 |
|              |          |          |        |     |      |        | 14.30                 |
|              | 1 month  | −13.22   | −8.7 to −17.8 | 2.32 | −5.70| <.001* | 16.50                 |
|              | 6 month  | −15.73   | −11.0 to −21.0 | 2.40 | −6.55| <.001* | 17.30                 |
|              | 1 year   | −16.07   | −11.0 to −20.4 | 2.55 | −6.29| <.001* | 14.30                 |
| Swallowing (n = 109) | Baseline | 11.63    | 6.1 to 17.2 | 2.86 | 4.07 | <.001* | 12.58                 |
|              |          |          |        |     |      |        | 16.70                 |
|              | Sx-RT    | +6.81    | −1.0 to +14.7 | 4.00 | 1.70 | .092   |                       |
|              | Sx-CRT   | +10.36   | +3.1 to +17.7 | 3.70 | 2.80 | .006   |                       |
|              | 1 month  | +10.12   | +4.9 to +15.4 | 2.66 | 3.80 | <.001* |                       |
|              | 6 month  | +5.46    | 0 to +10.8  | 2.76 | 1.98 | .049   |                       |
|              | 1 year   | +1.06    | −4.7 to +6.9 | 2.93 | .36  | .719   |                       |
| Senses (n = 109) | Baseline | 16.12    | 11.4 to 20.9 | 2.39 | 6.73 | 17.99  |                       |
|              |          |          |        |     |      |        | 15.54                 |
|              | 1 month  | +1.57    | −3.4 to +6.6 | 2.51 | .63  | .533   |                       |
|              | 6 month  | +8.92    | +3.8 to +14.2 | 2.60 | 3.43 | <.001* |                       |
|              | 1 year   | +2.24    | −3.1 to +7.8 | 2.77 | .81  | .419   |                       |
| Speech (n = 108) | Baseline | 19.93    | 15.9 to 24.1 | 2.09 | 9.53 | 12.96  |                       |
|              |          |          |        |     |      |        | 15.73                 |
|              | 1 month  | +3.64    | −1.4 to +8.6 | 2.51 | 1.45 | .149   |                       |
|              | 6 month  | +2.78    | −2.5 to +7.7 | 2.62 | 1.04 | .302   |                       |
|              | 1 year   | −.68     | −6.1 to +4.8 | 2.77 | −.25 | .806   |                       |
| Eating (n = 108) | Baseline | 20.50    | 13.2 to 27.8 | 3.69 | 5.55 | 15.78  |                       |
|              |          |          |        |     |      |        | 21.84                 |
|              | Sx-RT    | +8.76    | −1.2 to +18.8 | 5.13 | 1.71 | .091   |                       |
|              | Sx-CRT   | +14.25   | +5.0 to +23.3 | 4.74 | 3.01 | .003*  |                       |
|              | 1 month  | +2.19    | −4.6 to +9.1 | 3.47 | .63  | .528   |                       |
|              | 6 month  | +3.12    | −4.0 to +10.3 | 3.63 | .86  | .392   |                       |
|              | 1 year   | −2.95    | −10.3 to +4.6 | 3.85 | −.77 | .445   |                       |
| Social Contact (n = 108) | Baseline | 10.47    | 6.7 to 14.4 | 1.96 | 5.33 | 13.09  |                       |
|              |          |          |        |     |      |        | 14.06                 |
|              | 1 month  | +4.26    | −2 to +8.8  | 2.26 | 1.89 | .060   |                       |
|              | 6 month  | +3.97    | −6 to +8.5  | 2.35 | 1.69 | .092   |                       |
|              | 1 year   | +3.94    | −8 to +8.8  | 2.49 | 1.59 | .114   |                       |
| Sexuality (n = 105) | Baseline | 26.11    | 19.5 to 32.9 | 3.40 | 7.68 | 22.52  |                       |
|              |          |          |        |     |      |        | 23.45                 |
|              | 1 month  | +1.71    | −6.1 to +9.5 | 3.93 | .44  | .664   |                       |
|              | 6 month  | +.51     | −7.6 to +8.4 | 4.07 | .13  | .901   |                       |
|              | 1 year   | −7.38    | −15.9 to +1.3 | 4.30 | −1.71| .088   |                       |
| Teeth (n = 109) | Baseline | 23.38    | 17.2 to 29.6 | 3.20 | 7.30 | 16.92  |                       |
|              |          |          |        |     |      |        | 26.13                 |
|              | 1 month  | −3.39    | −11.5 to +4.9 | 4.19 | −.81 | .419   |                       |
|              | 6 month  | −1.96    | −10.3 to +6.5 | 4.30 | −.46 | .649   |                       |
|              | 1 year   | +.24     | −8.8 to +9.3 | 4.64 | .05  | .958   |                       |
| Open Mouth (n = 109) | Baseline | 14.65    | 7.4 to 21.9 | 3.71 | 3.94 | 14.56  |                       |
|              |          |          |        |     |      |        | 23.62                 |
|              | Sx-RT    | +2.24    | −7.6 to +12.0 | 5.05 | .44  | .659   |                       |
|              | Sx-CRT   | +14.59   | +5.5 to +23.7 | 4.68 | 3.12 | .002*  |                       |
|              | 1 month  | +12.42   | +5.2 to +19.6 | 3.71 | 3.35 | <.001* |                       |
|              | 6 month  | +11.30   | +3.7 to +18.9 | 3.88 | 2.92 | .004   |                       |
|              | 1 year   | +2.86    | −5.3 to +11.0 | 4.13 | .69  | .490   |                       |
research in HNC. Results indicated no significant differences in swallowing function by 6 months post-surgery and no significant differences in speech function by 1 year post-surgery compared with baseline. Decrements in multiple domains regarding quality of life were reported at all three post-operative follow-up assessments relative to baseline scores. Furthermore, treatment (by time) effects were revealed for swallowing and quality of life outcomes but not for speech outcomes.

**Speech function**

Patients reported statistically significantly worse SHI scores at 1- and 6-months post-operation compared with pre-operative scores. These findings indicate that by the 1 year follow-up assessment, speech function was no longer statistically different from baseline levels. However, estimated mean total SHI scores for the combined cohort indicated clinically relevant (> 6 points) speech impairment at all four assessment time points (mean estimates 20.9 to 30.8). Previous investigations indicate that patients treated for oral cancer experience long-term speech problems [12, 17, 18]. For example, in a cross-sectional study of patients with head and neck cancer that were an average of 78 months out of surgery (with or without C/RT), Dwivedi et al. [12] reported a mean total SHI score of 34.4 for the oral cavity cancer subgroup, suggesting speech impairment may be present many years following surgical intervention.

No differences in Psychosocial scores were revealed for any comparison period in the present study, suggesting that psychosocial aspects of speech function were not significantly impaired post-operatively relative to baseline. Similarly, in a cross-sectional study of oral and oropharyngeal patients between 6 and 155 months out of surgery (with or without RT), patients reported more functional than psychosocial problems [27]. Treatment, and treatment by time effects were not revealed for any of the subscales of the SHI in the present study, suggesting that treatment modality does not differentially influence the functional or psychosocial aspects of speech in

**Table 4** Mixed effects linear regression models for EORTC Quality of Life Questionnaire Head and Neck Module (EORTC-H&N35) (Continued)

| Subscale                     | Treatment 1 | 95% CI               | Treatment 2 | 95% CI               | Treatment 3 | 95% CI               |
|------------------------------|-------------|----------------------|-------------|----------------------|-------------|----------------------|
| **Dry Mouth** (n = 109)      |             |                      |             |                      |             |                      |
| Baseline                     | 28.91       | 19.2 to 38.5         | 4.93        | 5.86                 | 18.26       | 24.89                |
| Sx-RT                        | −15.39      | −31.2 to +6          | 8.05        | −1.91                | .057        |                      |
| Sx-CRT                       | −6.05       | −20.4 to +8.4        | 7.32        | −83                  | .409        |                      |
| 1 m x Sx                     | +8.23       | −40.0 to +20.1       | 6.13        | 1.34                 | .180        |                      |
| 6 m x Sx                     | +5.08       | −7.4 to +17.5        | 6.39        | .80                  | .428        |                      |
| 1 y x Sx                     | +6.16       | −7.1 to +20.0        | 6.87        | .90                  | .371        |                      |
| 1 m x Sx-R/RT                | +3.83       | −15.5 to +23.7       | 10.11       | .38                  | .705        |                      |
| 6 m x Sx-R/RT                | +42.18      | +22.5 to +62.9       | 10.18       | 4.14                 | <.001*      |                      |
| 1 y x Sx-R/RT                | +35.27      | +13.7 to +56.9       | 10.96       | 3.22                 | .001*       |                      |
| 1 m x Sx-CRT                 | +14.88      | −3.0 to +32.5        | 9.12        | 1.63                 | .104        |                      |
| 6 m x Sx-CRT                 | +36.45      | +17.8 to +55.0       | 9.63        | 3.79                 | <.001*      |                      |
| 1 y x Sx-CRT                 | +33.03      | +13.0 to +52.6       | 10.18       | 3.25                 | .001*       |                      |
| **Sticky Saliva** (n = 109)  |             |                      |             |                      |             |                      |
| Baseline                     | 25.74       | 19.3 to 32.3         | 3.34        | 7.72                 | 18.80       | 26.18                |
| 1 month                      | +7.69       | −7.0 to +15.8        | 4.17        | 1.85                 | .066        |                      |
| 6 month                      | +15.30      | +6.7 to +23.9        | 4.35        | 3.53                 | <.001*      |                      |
| 1 year                       | +15.34      | +6.2 to +24.5        | 4.63        | 3.33                 | .001*       |                      |
| **Cough** (n = 109)          |             |                      |             |                      |             |                      |
| Baseline                     | 17.74       | 13.4 to 22.0         | 2.20        | 8.05                 | 12.20       | 17.56                |
| 1 month                      | +3.82       | −1.4 to +9.2         | 2.78        | 1.38                 | .170        |                      |
| 6 month                      | +6.28       | +4.5 to +12.0        | 2.90        | 2.16                 | .032        |                      |
| 1 year                       | −3.08       | −9.2 to +3.00        | 3.08        | −1.00                | .318        |                      |

**Note.** *p < .0028; Models with treatment, time, and treatment x time interaction: Baseline = pre-operative mean estimate for surgery only group; Sx-RT/Sx-CRT = difference between pre-operative mean scores and baseline for surgery and radiotherapy, and, surgery and chemoradiotherapy groups, respectively; 1 m/6 m/1 y x Sx/Sx-R/RT/Sx-CRT = difference between mean subscale scores and baseline at 1 month; 6 months, and 1 year post-operation, respectively, for the surgery only, surgery and radiotherapy, and, surgery and chemoradiotherapy groups, respectively; Models with treatment and time (no interaction term): Baseline = pre-operative mean estimate for surgery only group; Sx-R/RT/Sx-CRT = difference between pre-operative mean scores and baseline for surgery and radiotherapy, and, surgery and chemoradiotherapy groups, respectively; 1 month/6 months/1 year = difference between mean subscale scores and baseline for respective assessment time point for combined cohort; *p-value for baseline scores not provided given that it tests the hypothesis that the baseline mean is significantly different from 0, results of which are not clinically meaningful; 95% CI calculated using bootstrapping approach.
patients surgically treated for oral cancer. Previous studies utilizing the SHI evaluated combined groups of patients with oral and oropharyngeal cancer [12, 17, 18, 27], and more diverse head and neck cancer subsites [28, 29], and were often cross-sectional in nature [12, 17, 18, 27, 28], limiting comparisons of study findings.

**Swallowing function**

Patient-reported swallowing outcomes revealed more difficulties with swallowing at 1 month post-operation compared with baseline. These swallowing difficulties affected patients' emotional states, physical and functional abilities. By 6 months post-operation, this difference was no longer apparent. Thus, only short-term declines in swallowing function were found for the present study cohort. However, when examining individual scores, clinically relevant impairments in swallowing function (≥ 20-point drop in MDADI subscale scores) were observed for approximately 20% of participants in the present study at 1 year post-operation compared with baseline. As such, while a return to baseline MDADI subscale scores was observed by 6 months post-operation for the study cohort, large individual differences in swallowing function were found.

To the authors' knowledge, no previous studies have longitudinally evaluated swallowing-related quality of life in patients surgically treated for tongue cancer using the MDADI. In a cross-sectional study of patients treated with primary surgery (+/- RT) who were on average 76 months post-treatment, mean MDADI scores for the oral cavity group were 71.7, 77.5, and 70.8 for the Emotional, Functional, and Physical subscales of the MDADI respectively [30]; these scores are similar to those observed in the present study. Another study found near-normal swallowing function for 26 patients treated for oral cavity SCCA assessed an average 15 years out of treatment [31]. Results of the present study and literature suggest that short-term decrements in swallowing function occur post-surgery in patients with oral SCCA, after which point patients start to recover their swallowing function, with patients reporting near-normal swallowing function many years post-treatment.

In the present study, patient-reported swallowing deficits were reported as worse by the Sx-CRT group compared to the Sx-RT group. These findings suggest that the addition of multiple adjuvant treatment interventions post-operation (i.e. chemo and RT) may negatively impact swallowing function. However, results of the present study may be confounded by differential disease progression before treatment. Published works on treatment influences on MDADI subscales are inconclusive. Shin et al. [6] reported significantly better swallowing capacity for glossectomy patients treated with surgery only compared with Sx-RT patients [6]. In contrast, Dwivedi et al. [30] found no statistically significant differences in mean MDADI subscales scores between the Sx, Sx-RT, and Sx-CRT groups of patients with oral or oropharyngeal cancer. Future work to discern if adjuvant C/RT affects post-operative patient-reported swallowing function in individuals with oral cancer is warranted.

**Quality of life related to head and neck cancer**

Clinically (>10 point) and statistically significant treatment by time interactions were revealed for only the Dry Mouth subscale of the EORTC-H&N35, with problems starting after the onset of radiation therapy. Dry mouth continued to be a significant problem at 1 year post-operation for both groups. No clinically or statistically significant differences in dry mouth were found between baseline and all post-operative assessments for the Sx only group. Nordgren et al. [32] also found that patients with oral carcinoma who were treated with surgery only did not have problems with dry mouth, while persistent severe problems with dry mouth over time (3 months, 1 year and 5 years post-treatment) were reported by patients in the RT and combined treatment groups [32]. Chronic dry mouth is known to be a common side effect of treatment, particularly as a result of radiation therapy for oral cancer treatment and is documented well in the literature [5, 9, 32–35].

In addition to the dry mouth subscale, negative treatment effects of Sx-CRT (but not Sx-RT) were revealed for swallowing, eating, and opening mouth; these results suggest that patients treated with multiple adjuvant regimens may be impacted more negatively than patients treated with adjuvant RT only. These differences may also reflect an underlying time dependent trend that was not strong enough to reach statistical significance. Alternatively, these differences may not be caused by treatment but may reflect pre-operative differences between treatment groups.

Decreased pain at all follow-up appointments compared with pre-treatment scores were found, indicating a positive result in symptomatology for patients undergoing surgical removal of an anterior tongue carcinoma. However, there were long term difficulties with sticky saliva (6 months and 1 year post-operation). Given the time horizon, the greater difficulties with sticky saliva that were found at 6 and 12 months post-operation compared with baseline for the combined cohort likely reflect the added negative effect of radiation, while short-term impairments in senses (taste and smell) and opening mouth may be a result of both surgical and/or radiation induced impairments.

Similar difficulties in multiple domains of quality of life in patients with oral cancer have been reported in the literature [5, 29, 36, 37]. Petruson et al. [5] conducted a longitudinal study of 90 patients with oral or
Conclusions

Results of the present study indicate that patients with cancer of the oral tongue who undergo surgical resection and reconstruction with or without adjuvant C/RT experience impairments in function and quality of life. Although SHI speech scores returned to baseline levels by the 1 year post-operation assessment, speech was clinically impaired at all assessment time points (baseline to 1 year post-operation). Short-term declines in swallowing function (MDADI and EORTC-H&N subscales) and most quality of life domains related to the head and neck returned to baseline levels by 1 year post-operation, while difficulties with dry mouth and sticky saliva persisted. A clear time trend of adjuvant (chemo)radiation therapy negatively affecting dry mouth scores over time was identified in this study, while negative independent effects of Sx-CRT on MDADI swallowing, and EORTC-H&N35 swallowing, eating, and opening mouth subscales were found.

Results of the present investigation will help guide clinical care and will be useful for patient counseling on expected short and long-term speech, swallowing, and quality of life outcomes of surgical and adjuvant treatment for oral cavity cancer. An increased utilization of patient-reported outcome measures in the literature reflects a move towards such patient-centred care.

Limitations of the present study include a large amount of missing responses (39%), clinical differences (i.e., T-stage and AJCC stage) found between responders and nonresponders at post-operative assessments, and the exclusion of other clinical and demographic variables such as sex, age, study site and TNM stage, in the mixed effects models due to risk of model overfit. Results of the present study suggest that treatment modality may differentially affect swallowing and quality of life outcomes in patients with oral cancer, while other studies also reported the influence of treatment modality [32], and other demographic and clinical factors (TNM stage, sex, age, tumour site) on speech [17], swallowing [6, 12, 38], and quality of life [32]. Future work to delineate how clinical and demographic factors differentially influence speech, swallowing and quality of life over time in patients treated for oral cavity cancer is warranted.
AD was the primary contributor to manuscript preparation; all authors were involved in manuscript preparation and approved the final version of the manuscript.

Ethics approval and consent to participate
This study received ethical approval from the Health Research Ethics Boards at each participating institution including University of Alberta (Pro00003670), Mount Sinai Beth Israel (188–10), and Hospital District of Southwest Finland (ETMK 33/180/2010).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Surgery, University of Alberta Hospital, Edmonton, AB T6G 2G4, Canada. 2Institute for Reconstructive Sciences in Medicine (iRSM), Misericordia Community Hospital, Edmonton, AB, Canada. 3Rehabilitation Medicine, Communication Sciences and Disorders, University of Alberta, Edmonton, AB, Canada. 4Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, AB, Canada. 5Division of Head and Neck Surgery, Department of Otolaryngology, Head & Neck Surgery, Mount Sinai Beth Israel, New York, NY, USA. 6Thyroid, Head And Neck Cancer (THANC) Foundation, New York, NY, USA. 7Department of Oral and Maxillofacial Surgery, Mount Sinai Beth Israel, New York, USA, 8Department of Oral and Maxillofacial Diseases, Turku University Hospital, Turku, Finland. 9Department of Oral and Maxillofacial Surgery, University of Turku, Turku, Finland. 10Department of Oto-Rhino-Laryngology, Turku University Hospital, Turku, Finland.

Received: 22 March 2017 Accepted: 28 August 2017

Published online: 04 September 2017

References
1. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009; 45(3):201–11.
2. Mantzopoulos K, Psychogios G, Künzel J, Waldfahrer F, Zenk J, Iro H. Primary surgical therapy for locally limited oral tongue cancer. Biomed Res Int. 2014; 2014:1–6.
3. Iyer NG, Tan DSW, Tan VK, Wang W, Hwang J, Tan N, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607.
4. Urken ML, Moscoso JF, Lawson W, Biller HF. A systematic approach to functional reconstruction of the oral cavity following partial and total glossectomy. Arch Otolaryngol Head Neck Surg. 1994;120(6):589–601.
5. Petruson K, Mercke C, Lundberg L, Silander E, Hammerlid E. Longitudinal evaluation of patients with cancer in the oral tongue, tonsils, or base of tongue – does interstitial radiation dose affect quality of life? Brachytherapy. 2005;4(4):271–7.
6. Shin YS, Koh YW, Kim S, Jeong JH, Ahn S, Hong HU, et al. Radiotherapy deteriorates postoperative functional outcome after partial glossectomy with free flap reconstruction. J Oral Maxillofac Surg. 2012;70(1):216–20.
7. Zhang H, Dziegielewski PT, Biron VL, Saudek J, Al-Qahatani KH, O’Connell DA, et al. Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis. J Otol Head Neck Surg. 2013;42(1):30–7.
8. Campbell BH, Marbella A, Layde PM. Quality of life and recurrence concern in survivors of head and neck cancer. Laryngoscope. 2000;110(6):895–906.
9. Crombie AK, Farah CS, Batstone MD. Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery. Br J Oral Maxillofac Surg. 2014;52(2):111–7.
10. Panchal J, Potterton AJ, Scanlon E, McLean NR. An objective assessment of speech and swallowing following free flap reconstruction for oral cavity cancers. Br J Plast Surg. 1996;49(6):363–9.
11. Archontaki M, Athanasiou A, Stavriasos D, Korkolis D, Faratzis G, Papadopoulou F, et al. Functional results of speech and swallowing after oral microvascular free flap reconstruction. Eur Arch Otorhinolaryngol. 2010; 267(11):1771–7.
12. Dwivedi RC, St. Rose S, Chisholm EJ, Bisase B, Aren F, Nutting CM, et al. Evaluation of speech outcomes using English version of the speech handicap index in a cohort of head and neck cancer patients. Oral Oncol. 2012;48(5):547–53.
13. Close LG, Truelson JM, Miledge RA, Schweitzer C. Sensory recovery in noninnervated flaps used for oral cavity and oropharyngeal reconstruction. Arch Otolaryngol Head Neck Surg. 1995;121(9):967–72.
14. Brown L, Rieger JM, Harris J, Seikalh Y. A longitudinal study of functional outcomes after surgical resection and microvascular reconstruction for oral cancer: tongue mobility and swallowing function. J Oral Maxillofac Surg. 2010;68(11):2690–6.
15. Loewen UJ, Boilek CA, Harris J, Seikalh Y, Rieger JM. Oral sensation and function; a comparison of patients with innervated radial forearm free flap reconstruction to healthy matched controls. Head Neck. 2010;32(1):85–95.
16. Hart DM, Daucy S, Escande C, Bretagne E, Janot F, Kolb F. Quality of life after free-flap tongue reconstruction. J Laryngol Otol. 2009;123(5):550–4.
17. Rinkel RN, Verdonck-de Leeuw IM, van Reij EJ, Aaronson NK, Leemans CR. Speech handicap index in patients with oral and pharyngeal cancer: better understanding of patients’ complaints. Head Neck. 2008;30(7):868–74.
18. Rinkel RN, Verdonck-de Leeuw IM, de Bree R, Aaronson NK, Leemans CR. Validity of patient-reported swallowing and speech outcomes in relation to objectively measured oral function among patients treated for oral or oropharyngeal cancer. Dysphagia. 2015;30(2):196–204.
19. Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson Dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7):870–6.
20. Hutcheson KA, Barrow MP, Litsec A, Barringer DA, Gries K, Lewin JS. What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients? Laryngoscope. 2016;126(5):1108–13.
21. Lu W, Wayne PM, Davis RB, Buring JE, Li H, Goguen LA, et al. Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012; 33(4):700–11.
22. Bjordal K, Hammerlid E, Alinier-Elmqvist M, de Graaff A, Boysen M, Eversen JF, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of cancer quality of life questionnaire-NH&NS. J Clin Oncol. 1999;17(3):1008–19.
23. Bjordal K, de Graaff A, Fayez PM, Hammerlid E, van Postelsberge C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Euro J Cancer. 2000;36(14):1796–807.
24. Pashier E, Stuiver M, van der Molen L, Kerkhof S, van den Brekel M, Hilgers F. Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients. Eur Arch Otorhinolaryngol. 2016;273(6):1577–87.
25. Aste M, Bonissegna M, Freno A, Trettin E. Techniques for dealing with incomplete data: a tutorial and survey. Pattern Anal Applic. 2015;18(1):1–19.
26. Spiro BM, Castille A, Bhatia S, Williams S, Elimelech B, Nutting CM, et al. First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. Head Neck. 2011; 33(3):341–8.
27. Rinkel RN, Verdonck-de Leeuw IM, Doornaert P, Buter J, de Bree R, Langendijk JA, et al. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SLH. Eur Arch Otorhinolaryngol. 2015;272(7):1849–55.
28. Lazarus C, Husaini H, Hu K, Culliney B, Li Z, Urken M, et al. Functional outcomes and quality of life after chemoradiotherapy: baseline and 3 and 6 months post-treatment. Dysphagia. 2014;29(3):365–75.
29. Dwivedi RC, Chisholm EJ, Khan AS, Harris NJ, Bhude SA, St Rose S, et al. An exploratory study of the influence of clinico-demographic variables on
swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery. Eur Arch Otorhinolaryngol. 2012;269(4):1233–9.

31. Thomas L, Moore EJ, Olsen KD, Kasperbauer JL. Long-term quality of life in young adults treated for oral cavity squamous cell cancer. Ann Otol Rhinol Laryngol. 2012;121(6):396–401.

32. Nordgren M, Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Boysen M, Jannert M. Quality of life in oral carcinoma: a 5-year prospective study. Head Neck. 2008;30(4):461–70.

33. Moore K, Ford P, Farah C. Support needs and quality of life in oral cancer: a systematic review. Int J Dent Hyg. 2014;12(1):36–47.

34. Jones DL, Rankin KV. Management of the oral sequelae of cancer therapy. Texas Dent J. 2012;129(5):461–8.

35. Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, Witte BI, de Bree R, Doornaert P, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol. 2013;49(5):443–8.

36. Borggreven PA, Aaronson NK, Verdonck-de Leeuw IM, Muller MJ, Heiligers MLCH, Bree R, et al. Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncol. 2007;43(10):1034–42.

37. Fang F, Tsai W, Chien C, Chiu H, Wang C, Chen H, et al. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncologia. 2005;68(4–6):405–13.

38. Yang CJ, Roh J, Choi KH, Kim M, Choi S, Nam SY, et al. Pretreatment Dysphagia inventory and videofluorographic swallowing study as prognostic indicators of early survival outcomes in head and neck cancer. Cancer. 2015;121(10):1588–98.